Stoke Therapeutics (STOK) news

Stoke completes first two OSPREY dose cohorts for STK-002

Stoke Therapeutics has completed the first two dose cohorts of its OSPREY clinical trial for STK-002, a gene therapy candidate targeting spinal muscular atrophy (SMA) type 1 . The trial is evaluating the safety, tolerability, and efficacy of STK-002 in infants with the most severe form of SMA, a…

Stoke Therapeutics completes successful meeting with FDA to

Stoke Therapeutics announces completion of successful meeting with the FDA to align on planned U.S. NDA for Zorevunersen, an investigational medicine for the treatment of Dravet syndrome

Stoke Therapeutics appoints Bo Cumbo to its board of directors, enhancing commercial expertise as the company advances Zorevunersen development toward potential FDA approval and commercialization

Stoke Therapeutics has announced the appointment of Bo Cumbo to its board of directors, marking a strategic move to strengthen its commercial capabilities as the company progresses in the development of Zorevunersen, an investigational antisense oligonucleotide therapy for the treatment of myotonic…

Stoke's Zorevunersen generally well tolerated over 5 years

Stoke Therapeutics has reported that its investigational drug Zorevunersen was generally well tolerated over a five-year period in clinical studies. The findings were shared by the company and highlight the long-term safety profile of the treatment, which is being developed for specific…